Onco Wiki / Biomarcador

Duplicação interna em tandem de FLT3 (ITD)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDBIO-FLT3-ITD
TipoBiomarcador
Alegais
FLT3 ITDFLT3-ITDFLT3-ITD-positive AMLВнутрішня тандемна дуплікація FLT3 (ITD)
Estadoreviewed 2026-04-27 | pending_clinical_signoff
DoençasDIS-AML DIS-B-ALL
FontesSRC-ELN-AML-2022 SRC-NCCN-AML-2025 SRC-QUANTUM-FIRST-ERBA-2023 SRC-RATIFY-STONE-2017

Fatos de biomarcadores

Tipo de biomarcadorgene_mutation
Detalhes da mutação{"exon": "14-15 (dominio juxtamembrana)", "functional_impact":"Constitutive FLT3 kinase activation through dimerization", "gene": FLT3, "gene_hugo_id": HGNC:3765, "variant_type":", "internal tandem duplication"}
Medição
MétodoPCR / fragment-length analysis (rapid TAT essential; required at AML diagnosis) OR NGS panel
UnidadesAllelic ratio (ITD-mutant : WT, e.g. 0.5 high-AR threshold per ELN-2017; ELN-2022 dropped AR threshold but still reported)
Requisito de sensibilidadeRapid PCR turn-around (≤72 h) required to inform 1L induction (midostaurin / quizartinib add-on per CALGB-10603 RATIFY / QuANTUM-First)
Biomarcadores relacionadosBIO-FLT3-D835 BIO-NPM1

Notas

~25% of newly diagnosed AML; high allelic ratio (≥0.5) historically associated with poorer outcomes (risk-stratifying in ELN-2017; ELN-2022 reclassified all FLT3-ITD as intermediate when NPM1-mutant irrespective of AR). Midostaurin + 7+3 (RATIFY) and quizartinib + 7+3 (QuANTUM-First) FDA-approved 1L. Gilteritinib (ADMIRAL) approved for relapsed/refractory FLT3-mutated AML. FLT3-ITD is also a maintenance target post-allo-HSCT (sorafenib SORMAIN; gilteritinib BMT-CTN-1506).

Usado por

Relevância terapêutica

Biomarcador